Nathan John Bryson

This profile gathers the share dealings of Nathan John Bryson in Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation). Over a trading history stretching from 24 March 2016 to 2 June 2017, the count stands at 6 filings.

No open-market sale appears; the market trades are 6 purchases worth €36k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. So far in 2017, the count stands at 2 purchases and no sales.

In size, the median ticket on the buying side is €5,994. The 6 purchases reviewed show no overlap with other insiders buying the same stock within a month.

The newest entry dates from 2 June 2017: an open-market purchase of €3,087, in Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation). Between a trade and the moment it shows up on SEDI, the median delay is 1 day. This delay matters because a trade only becomes useful information once it is public. Source: insider filings from SEDI. Past trades are no guide to future returns.